Global Intravenous Immunoglobulin Market Report and Forecast 2024-2032

Global Intravenous Immunoglobulin Market Outlook 

The global intravenous immunoglobulin market is expected to grow at a CAGR of 6.90% between 2024 and 2032. The market is being driven by increasing prevalence of immunodeficiency diseases and rising adoption of intravenous immunoglobulin treatments.  

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Key Trends in the Market 

Intravenous immunoglobulin or IVIG is a therapy treatment targeted towards patients deficient of antibodies that would otherwise fight infections or are suffering from autoimmune diseases. Immunoglobulins are prepared by the immune system of people who are healthy and have sufficient antibodies. IVIG treatment response varies from person to person, and there is a likelihood that some patients may not respond to the treatment.

• A wide number of conditions can be treated with IVIG therapy. The increasing adoption rate for the intravenous immunoglobulin therapy because of the safety and efficacy it provides is expected to drive the growth of the intravenous immunoglobulin market.

• COVID-19 has impacted the health of the people and weakening the immune systems of many worldwide. Intravenous immunoglobulin therapy treatment can prove effective in such cases, by boosting the weakened immune systems.

• Intravenous immunoglobulin therapy may be cost prohibitive as it is a long-term therapy with costs varying depending upon the severity of the original condition. Lowering costs are a key trend for the global market for intravenous immunoglobulin that can support its long term growth.

• Geriatric populations are also likely to have weakened immune systems, increasing their susceptibility to other illnesses. IVIG treatment can help improve the health of such populations, increasing their overall lifespan.

Market Analysis 

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Based on form, the intravenous immunoglobulin market can be bifurcated into liquid and lyophilised. On the basis of product the market can be divided into IGG, IGA, IGM, IGE, and IGD. Based on indication, the market is segmented into chronic inflammatory demyelinating polyneuropathy (CIDP), idiopathic thrombocytopenic purpura (ITP),  Guillain-Barre syndrome, myasthenia gravis, multifocal motor neuropathy (MMN), Kawasaki disease, hypogammaglobulinemia, and chronic lymphocytic leukaemia, among others. 

By distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, and others. Based on end use the market is divided into hospitals, clinics, and home care. The regional markets can be categorised into North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa.  

The comprehensive EMR report provides an in-depth assessment of the market based on the Porter's five forces model along with giving a SWOT analysis. The report gives a detailed analysis of the following key players in the global intravenous immunoglobulin market, covering their competitive landscape and latest developments like mergers, acquisitions, investments, and expansion plans.  

• CSL Limited

• Grifols, S.A.

• Octapharma AG

• Shanghai RAAS Blood Products Co., Ltd.

• Biotest AG

• LFB S.A

• Others

Market Share by Form

The liquid form segment of the intravenous immunoglobulin market accounts for a substantial share, due to the ease of administering liquids intravenously, without concerns of mixing powders in required concentrations. Liquid immunoglobulin is collected from the blood plasma of the individuals only after screening them and making sure that they are healthy. The blood plasma collected is purified and is tested for serious infections such as AIDS and hepatitis. 

Lyophilised or powder form of intravenous immunoglobulin is administered within 2-3 hours of its dissolution. It offers greater flexibility in changing dosages for patients new to the treatment and trying out various concentrations to find an ideal match. 

Market Share by End Use

Intravenous immunoglobulin is typically given to patients in hospitals or clinics but in some cases it can be administrated through home care, under careful supervision of a professional nurse. As IVIG treatment tends to be long-term, many patients start out with treatments in hospitals or clinics, and later moving on to home care. 

Administration of intravenous immunoglobin through home care is preferable for long-term treatment as it is more comfortable for patients to receive treatment in the comfort of their own home, due to which growth of the home care segment in the intravenous immunoglobulin market is expected. Depending upon the region and insurance coverage, home care may or may not be more expensive than receiving intravenous immunoglobin in hospitals or clinics. 

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Competitive Landscape 

CSL Limited founded in 1916 has its headquarter in Melbourne, Australia. This biotechnology company mainly focusses on innovating medical solutions to treat bleeding disorders, neurological disorders, and other disorders or medical problems. 

Grifols, S.A. was established in 1940 and has its headquarter in Barcelona, Spain. It is a pharmaceutical and chemical manufacturer known for the development of blood-plasma based products. It also supplies reagents, devices, and instruments for laboratories involved in clinical testing.

Octapharma AG was incorporated in 1983 and has its headquarter in Lachen, Switzerland. It is a family owned company and develops human proteins from human cell lines and plasma. They typically manufacture products that treat bleeding disorders and other rare diseases. 

Other market players include Shanghai RAAS Blood Products Co., Ltd., Biotest AG, and LFB S.A, among others.

Key Highlights of the Report